Evidence of the efficacy of hypocholesterolemic treatment in primary and secondary prevention of ischemic heart disease;Evidencias de la eficacia del tratamiento hipocolesterolemiante en la prevención primaria y secundaria de la cardiopatía isquémica

Medicina Clinica

Volumn 114, Issue SUPPL. 2, 2000, Pages 1-10

  Walther, Luis Antonio Álvarez Sala ^a   Núñez Cortés, Jesús Millán ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cardiovascular risk; Cholesterol; Lipoproteins; Statins

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

AGED; ANGIOGRAPHY; BLOOD; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; EXERCISE; FEMALE; GENETICS; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIMARY HEALTH CARE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANGIOGRAPHY; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; EXERCISE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PRIMARY HEALTH CARE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033648990     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Aschoff L. Das Gehalt an Cholesterin der atheromatösen Aorten. Verh Deutach Path Ges 1906; 10: 166.
2. Böttcher CJF, Woodfor FP, Romeny-Watcher CTH, Van Houte EB, Van Gent CM. Fatty acid distribution in lipids of the aortic wall. Lancet 1960; 1: 1378-1381.
3. Small DM. Progression and regression of atherosclerotic lesions. Insight from lipid physical biochemistry. Arteriosclerosis 1988; 8: 103-129.
4. Alvarez-Sala LA, Garcés C, De Oya M. Realidad y falacia de la inflamación en la ateromatosis. En: Espinós D, editor. Inflamación y enfermedad. Madrid: Panamericana, 1997; 63-96.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
6. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994; 90: 2267-2279.
7. Freed M, Safian RD, O'Neil WW, Safian M, Jones D, Grines CL. Combination of lovastatin, enalapril and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995; 76: 1185-1188.
8. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Incidence and development of atherosclerosis and xanthoma. Atherosclerosis 1980; 36: 261-268.
9. Kita T, Brown MS, Watanabe Y, Goldstein JL. Deficiency of LDL receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA 1981; 78: 2268-2272.
10. Seddon AM, Woolf N, La Ville A, Pittilo RM, Rowles PM, Turner PR et al. Hereditary hiperlipidemia in the rabbit due to overproduction of lipoproteins. II. Preliminary report of arterial pathology. Arteriosclerosis 1987; 7: 113-124.
11. Scanu AM, Khalil A, Neven L, Tidore M, Dawson G, Pfaffinger D et al. Genetically determined hypercholesterolemia in a Rhesus monkey due to a deficiency of the LDL receptor deficiency. J Lipid Res 1988; 29: 1671-1681.
12. Anitschkow N, Chalatow S. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Enstehung einiger pathologischen Prozesse. Zentralbl Allg Pathol Pathol Anal 1913; 24: 1-9.
13. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet. Metabolism 1965; 14: 747-758.
14. Keys A, Fidanza F, Scardi V, Blackburn H, Menotti A, Buzina R et al. Studies on serum cholesterol and other characteristics on clinical healthy men in Naples. Arch Intern Med 1954; 93: 328-335.
15. a ed.). Nueva York: McGraw Hill, 1989; 1215-1250.
16. Thompson GR, Seed M, Nthyananthan S, McCarthy S, Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 1989; 9 (Supl 1): 75-80.
17. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG, Campbell ED et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-1568.
18. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL et al. Familial defective apolipoprotein B100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84: 6919-6923.
19. Documento conjunto para la prevención del riesgo cardiovascular. Estrategias. Barcelona: Delfer Arts Gràfiques, 1996.
20. Glueck CJ, Fallat RW, Millet F, Gartside P, Elston RC, Go RCP. Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds. Metabolism 1975; 24: 1243-1265.
21. Brunner D, Weisbort J, Meshulam N, Kaufmann N, Klein LW, Stein EA et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987; 59: 1271-1276.
22. Badimón JJ, Badimón L, Gálvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989; 60: 455-461.
23. Kannel WD, Dawber TR, Kagan A, Revotsie N, Stokes J. Factors of risk in the development of coronary heart disease. Six-years follow-up experience: the Framingham Study. Ann Intern Med 1961; 55: 33-39.
24. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling Project. J Chronic Dis 1978; 31: 201-306.
25. Keys A. Coronary heart disease in Seven Countries. Circulation 1970; 41 (Supl 1): 1-211.
26. Keys A. Seven Countries. A multivariate analysis of death and coronary heart disease. Cambridge (Massachussetts): Harvard University Press, 1980; 1-381.
27. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828.
28. De Langen CD. Cholesterine-stofwisseling en rassenpathologie. Geneeskd Tydsch V Nederl Indie 1916; 56: 1-34.
29. Kagan A, Harris BR, Winkelstein W Jr, Popper J, Rhoads GG, Takeya Y et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan. Hawaii and California. Demographic, physical, dietary and biochemical characteristics. J Chronic Dis 1974; 27: 345-364.
30. Murray CJL, López AD. Mortality in the world in the next 25 years. Lancet 1997; 349: 1269-1276.
31. Lipid Research Clinics Program. The Lipid Research Clinic Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
32. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
33. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-3240.
34. Cashin Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-years follow-up. JAMA 1990; 264: 3013-3017.
35. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336: 129-133.
36. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569.
37. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
38. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients from hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955.
39. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-3012.
40. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin Hemphill L, Hodis HN et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-976.
41. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-638.
42. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, McGovern ME, for the Plac I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Am Coll Cardiol 1994; 131: 739-745.
43. Jukema JW, Bruschke AV, Van Boven AJ, Reiber JH, Bal ET, Zwinderman AH et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Stalin Study (REGRESS). Circulation 1995; 91: 2528-2540.
44. Patterson DHL, Treasure J. The culprit coronary lesion. Lancet 1991; 338: 1379-1380.
45. Katz DR. The culprit lesion. Curr Opin Lipidol 1992; 3: 257-262.
46. Fuster V, Stein B, Ambrose BA, Badimon L, Badimón JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990; 82 (Supl 2): 47-59.
47. De Feyter PJ, Serruys PW, Davies MJ, Richardson P, Lubsen J, Oliver MF. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials. Circulation 1991; 84: 422-423.
48. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA et al.-Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
49. Correia LC, Atalar E, Kelemen MD, Ocali O, Hutchins GM, Fleg JL et al. Intravascular magnetic resonance imaging of atherosclerotic plaque composition. Arterioscler Thromb Vasc Biol 1997; 17: 3626-3632.
50. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
51. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physiochemical and histological changes in the arterial wall of non-human primates during progression and regression of atherosclerosis. J Clin Invest 1984; 73: 1590-1605.
52. Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res 1972; 30: 675-680.
53. Clarkson TB, Bond MG, Catchatourian R, Bollock BC, Marzetta CA. A study of atherosclerosis regression in Macaca mulata. IV. Changes in coronary arteries from animals with atherosclerosis for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol 1981; 34: 345-368.
54. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophages, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
55. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
56. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J et al. Regular physical exercise and low-fat diet. Effect on progression of coronary artery disease. Circulation 1992; 86: 1-11.
57. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II Coronary Intervention Study. Circulation 1984; 69: 313-324.
58. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Bocuzzi SJ et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-968.
59. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T et al. Effect of lovastatin on premature carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-1687.
60. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-459.
61. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-1764.
62. Criqui MH. Cholesterol, primary and secondary prevention, and all-cause mortality. Ann Intern Med 1991; 115: 973-976.
63. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707.
64. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Ann Intern Med 1991: 115: 687-693.
65. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. Br Med J 1971; 4: 767-775.
66. Carlson IA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-418.
67. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
68. Leren P. The Oslo diet-heart study. Eleven years report. Circulation 1970; 42: 935-942.
69. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1112-1119.
70. Gould AL, Rossouw J, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look to old data. Circulation 1995; 91: 2274-2282.
71. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
72. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-1275.
73. Pedersen TR, Kjekshus J, Olsson AG, Cook TJ. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dl in patients with CHD [resumen]. Circulation 1997; 96: 1-716.
74. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 156-162.
75. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
76. National Expert Panel. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-1445.
77. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
78. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-1459.
79. Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N et al. Cretan Mediterranean diet for prevention of coronary heart disease. Am J Clin Nutr 1995; 61: S1360-S1367.
80. Dayton S, Pearce ML, Hashimoto S, Wilfrid JD, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 39/40 (Supl 2): 1-63.
81. Frantz ID, Dawson EA, Kuba K, Brewer ER, Gatewood LC, Bartch GE. The Minnesota Coronary Survey: effect of diet on cardiovascular events and deaths. Circulation 1975; 51-52 (Supl 1): 1-4.
82. Frantz ID, Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary survey. Arteriosclerosis 1989; 9: 129-135.
83. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118.
84. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki Heart Study: Primary Prevention Trial with gemfibrozil in middle-aged men with dyslipemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
85. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients. Effect on serum cholesterol and mortality. J Chronic Dis 1978; 31: 5-14.
86. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 303: 276-282.
87. Oliver MF. Reducing cholesterol does not reduce mortality. J Am Coll Cardiol 1988; 12: 814-817.
88. Oliver MF. Might treatment of hypercholesterolemia increase non-cardiac mortality? Lancet 1991; 337: 1529-1531.
89. Marmot M. The cholesterol papers. Lowering population cholesterol probably isn't harmful. BMJ 1994; 308: 351-352.
90. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
91. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
92. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
93. Sociedad Española de Arteriosclerosis, Sociedad Española de Medicina Interna, Liga Española para la lucha contra la Hipertensión Arterial. Recomendaciones para la prevención primaria de la enfermedad cardiovascular. Clin Invest Arteriosclerosis 1994; 6: 62-102.
94. Sociedad Española de Arteriosclerosis y Sociedad Española de Cardiología. Evidencias clínico-experimentales y recomendaciones para el tratamiento de la hiperlipemia en los pacientes con cardiopatia isquémica. Documento Consenso de la Sociedad Española de Arteriosclerosis y la Sociedad Española de Cardiología. Clin Invest Arteriosclerosis 1994; 6: 103-111.
95. Pearson TA. Lipid-lowering therapy in low risk patients. JAMA 1998; 279: 1659-1661.